Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.610
+0.050 (3.21%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 6.25, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 300.64% from the current stock price of 1.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +476.92% | Apr 28, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +156.41% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +476.92% | Mar 24, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +92.31% | Mar 6, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +28.21% | Feb 9, 2026 |
Financial Forecast
Revenue This Year
30.48M
from 14.56M
Increased by 109.40%
Revenue Next Year
15.22M
from 30.48M
Decreased by -50.06%
EPS This Year
-0.06
from -0.28
EPS Next Year
-0.08
from -0.06
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.8M | 27.8M | ||||||
| Avg | 30.5M | 15.2M | ||||||
| Low | 8.3M | 5.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 317.7% | -9.0% | ||||||
| Avg | 109.4% | -50.1% | ||||||
| Low | -43.2% | -82.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.12 | 0.02 | ||||||
| Avg | -0.06 | -0.08 | ||||||
| Low | -0.14 | -0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.